Nexgard Spectra

Free Worldwide Shipping

For all treatments over $20
No coupon required

Free shippingon all treatments

What is NexGard Spectra for Dogs?

NexGard Spectra is an upgraded formula of the original NexGard, which controls tick and flea infestations on dogs. NexGard Spectra contains an additional active ingredient (Milbemycin Oxime) that protects your pet against heartworms and other intestinal parasites.

This means that with the administration of a single monthly chewable you can: kill fleas, kill ticks (including Rocky Mountain wood tick, brown dog tick), prevent the development of heartworm, and control roundworms, hookworms and whipworms.

As with all heartworm medications, this is a preventative measure and it is important that your dog is first tested for existing heartworm.

Benefits

Broad-spectrum treatment protects from multiple parasites

Fast acting formula kills fleas in 6-8 hours

Comes in a tasty beef-flavored chew for easy administration

No more mess from topical preventatives

Is NexGard Spectra suitable for my dog?

NexGard Spectra is suitable for use with dogs and puppies from 8 weeks of age, with a minimum body weight of 4.5 lbs (2 kg). NexGard Spectra has not been evaluated as safe for use on pregnant or lactating dogs.

Dosage Schedule

NexGard Spectra is given as a once-a-month chewable, with the exact dosage based on your dog’s body weight.

NexGard Spectra may be offered to your dog by hand, or broken up into pieces and included with their food. If hidden in food, make sure that the tablet has been swallowed. It is not necessary to administer the chewable with a meal.

What are the side effects of NexGard Spectra?

Reported side effects include vomiting, diarrhea, lethargy and loss of appetite.

What precautions must be taken?

Keep out of reach children and animals.

Not for human use.

Not for feline use.

Do not give to dogs under 8 weeks of age.

Do not give to dogs weighing less than 4.5 lbs (2kg).

The safe use of NexGard Spectra with breeding, pregnant or lactating dogs has not been evaluated.